Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study
The St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pathologica...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| Repositorio: | r-FISABIO. Repositorio Institucional de Producción Científica |
| OAI Identifier: | oai:fisabio.fundanetsuite.com:p9184 |
| Acceso en línea: | https://fisabio.portalinvestigacion.com/publicaciones/9184 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102707447&doi=10.1038%2fs41598-021-84825-2&partnerID=40&md5=37b8de0da2809d23dbd52bac756ec926 |
| Access Level: | acceso abierto |
| Palabra clave: | Adult Aged Breast Neoplasms Chemotherapy, Adjuvant Disease-Free Survival Female Follow-Up Studies Humans Middle Aged Models, Biological Neoplasm Staging Retrospective Studies Spain Survival Rate adjuvant chemotherapy adult aged biological model breast tumor cancer staging clinical trial disease free survival epidemiology female follow up human metabolism middle aged mortality multicenter study retrospective study survival rate |
| id |
ES_97f1300e0bf7bc23ce0743733df2efbb |
|---|---|
| oai_identifier_str |
oai:fisabio.fundanetsuite.com:p9184 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain studyGómez-Acebo IDierssen-Sotos TMirones MPérez-Gómez BGuevara MAmiano PSala MMolina AJAlonso-Molero JMoreno VSuarez-Calleja CMolina-Barceló AAlguacil JMarcos-Gragera RFernández-Ortiz MSanz-Guadarrama OCastaño-Vinyals GGil-Majuelo LMoreno-Iribas CAragonés NKogevinas MPollán MLlorca JAdultAgedBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleFollow-Up StudiesHumansMiddle AgedModels, BiologicalNeoplasm StagingRetrospective StudiesSpainSurvival Rateadjuvant chemotherapyadultagedbiological modelbreast tumorcancer stagingclinical trialdisease free survivalepidemiologyfemalefollow uphumanmetabolismmiddle agedmortalitymulticenter studyretrospective studySpainsurvival rateThe St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pathological stage <3 in Spain between 2008 and 2013 was begun and then followed-up until 2017/2018. Data on patient and tumour characteristics were obtained from medical records, as well as their first line treatment. First line treatments were classified in three categories, according on whether they included the main St Gallen-2013 recommendations, more than those recommended or less than those recommended. Multinomial logistic regression models were carried out to identify factors associated with this classification and Weibull regression models were used to find out the relationship between this classification and survival. About half of the patients were treated according to St Gallen recommendations; 21% were treated over what was recommended and 33% received less treatment than recommended. Factors associated with treatment over the recommendations were stage II (relative risk ratio [RRR]=4.2, 2.9-5.9), cancer positive to either progesterone (RRR=8.1, 4.4-14.9) or oestrogen receptors (RRR=5.7, 3.0-11.0). Instead, factors associated with lower probability of treatment over the recommendations were age (RRR=0.7 each 10 years, 0.6-0.8), poor differentiation (RRR=0.09, 0.04-0.19), HER2 positive (RRR=0.46, 0.26-0.81) and triple negative cancer (RRR=0.03, 0.01-0.11). Patients treated less than what was recommended in St Gallen had cancers in stage 0 (RRR=21.6, 7.2-64.5), poorly differentiated (RRR=1.9, 1.2-2.9), HER2 positive (RRR=3.4, 2.4-4.9) and luminal B-like subtype (RRR=3.6, 2.6-5.1). Women over 65 years old had a higher probability of being treated less than what was recommended if they had luminal B-like, HER2 or triple negative cancer. Treatment over St Gallen was associated with younger women and less severe cancers, while treatment under St Gallen was associated with older women, more severe cancers and cancers expressing HER2 receptors.NATURE PORTFOLIO2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/9184https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102707447&doi=10.1038%2fs41598-021-84825-2&partnerID=40&md5=37b8de0da2809d23dbd52bac756ec926Scientific ReportsISSN: 20452322reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p91842026-06-11T12:45:17Z |
| dc.title.none.fl_str_mv |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| title |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| spellingShingle |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study Gómez-Acebo I Adult Aged Breast Neoplasms Chemotherapy, Adjuvant Disease-Free Survival Female Follow-Up Studies Humans Middle Aged Models, Biological Neoplasm Staging Retrospective Studies Spain Survival Rate adjuvant chemotherapy adult aged biological model breast tumor cancer staging clinical trial disease free survival epidemiology female follow up human metabolism middle aged mortality multicenter study retrospective study Spain survival rate |
| title_short |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| title_full |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| title_fullStr |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| title_full_unstemmed |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| title_sort |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| dc.creator.none.fl_str_mv |
Gómez-Acebo I Dierssen-Sotos T Mirones M Pérez-Gómez B Guevara M Amiano P Sala M Molina AJ Alonso-Molero J Moreno V Suarez-Calleja C Molina-Barceló A Alguacil J Marcos-Gragera R Fernández-Ortiz M Sanz-Guadarrama O Castaño-Vinyals G Gil-Majuelo L Moreno-Iribas C Aragonés N Kogevinas M Pollán M Llorca J |
| author |
Gómez-Acebo I |
| author_facet |
Gómez-Acebo I Dierssen-Sotos T Mirones M Pérez-Gómez B Guevara M Amiano P Sala M Molina AJ Alonso-Molero J Moreno V Suarez-Calleja C Molina-Barceló A Alguacil J Marcos-Gragera R Fernández-Ortiz M Sanz-Guadarrama O Castaño-Vinyals G Gil-Majuelo L Moreno-Iribas C Aragonés N Kogevinas M Pollán M Llorca J |
| author_role |
author |
| author2 |
Dierssen-Sotos T Mirones M Pérez-Gómez B Guevara M Amiano P Sala M Molina AJ Alonso-Molero J Moreno V Suarez-Calleja C Molina-Barceló A Alguacil J Marcos-Gragera R Fernández-Ortiz M Sanz-Guadarrama O Castaño-Vinyals G Gil-Majuelo L Moreno-Iribas C Aragonés N Kogevinas M Pollán M Llorca J |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Adult Aged Breast Neoplasms Chemotherapy, Adjuvant Disease-Free Survival Female Follow-Up Studies Humans Middle Aged Models, Biological Neoplasm Staging Retrospective Studies Spain Survival Rate adjuvant chemotherapy adult aged biological model breast tumor cancer staging clinical trial disease free survival epidemiology female follow up human metabolism middle aged mortality multicenter study retrospective study Spain survival rate |
| topic |
Adult Aged Breast Neoplasms Chemotherapy, Adjuvant Disease-Free Survival Female Follow-Up Studies Humans Middle Aged Models, Biological Neoplasm Staging Retrospective Studies Spain Survival Rate adjuvant chemotherapy adult aged biological model breast tumor cancer staging clinical trial disease free survival epidemiology female follow up human metabolism middle aged mortality multicenter study retrospective study Spain survival rate |
| description |
The St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pathological stage <3 in Spain between 2008 and 2013 was begun and then followed-up until 2017/2018. Data on patient and tumour characteristics were obtained from medical records, as well as their first line treatment. First line treatments were classified in three categories, according on whether they included the main St Gallen-2013 recommendations, more than those recommended or less than those recommended. Multinomial logistic regression models were carried out to identify factors associated with this classification and Weibull regression models were used to find out the relationship between this classification and survival. About half of the patients were treated according to St Gallen recommendations; 21% were treated over what was recommended and 33% received less treatment than recommended. Factors associated with treatment over the recommendations were stage II (relative risk ratio [RRR]=4.2, 2.9-5.9), cancer positive to either progesterone (RRR=8.1, 4.4-14.9) or oestrogen receptors (RRR=5.7, 3.0-11.0). Instead, factors associated with lower probability of treatment over the recommendations were age (RRR=0.7 each 10 years, 0.6-0.8), poor differentiation (RRR=0.09, 0.04-0.19), HER2 positive (RRR=0.46, 0.26-0.81) and triple negative cancer (RRR=0.03, 0.01-0.11). Patients treated less than what was recommended in St Gallen had cancers in stage 0 (RRR=21.6, 7.2-64.5), poorly differentiated (RRR=1.9, 1.2-2.9), HER2 positive (RRR=3.4, 2.4-4.9) and luminal B-like subtype (RRR=3.6, 2.6-5.1). Women over 65 years old had a higher probability of being treated less than what was recommended if they had luminal B-like, HER2 or triple negative cancer. Treatment over St Gallen was associated with younger women and less severe cancers, while treatment under St Gallen was associated with older women, more severe cancers and cancers expressing HER2 receptors. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://fisabio.portalinvestigacion.com/publicaciones/9184 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102707447&doi=10.1038%2fs41598-021-84825-2&partnerID=40&md5=37b8de0da2809d23dbd52bac756ec926 |
| url |
https://fisabio.portalinvestigacion.com/publicaciones/9184 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102707447&doi=10.1038%2fs41598-021-84825-2&partnerID=40&md5=37b8de0da2809d23dbd52bac756ec926 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
NATURE PORTFOLIO |
| publisher.none.fl_str_mv |
NATURE PORTFOLIO |
| dc.source.none.fl_str_mv |
Scientific Reports ISSN: 20452322 reponame:r-FISABIO. Repositorio Institucional de Producción Científica instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| instname_str |
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| reponame_str |
r-FISABIO. Repositorio Institucional de Producción Científica |
| collection |
r-FISABIO. Repositorio Institucional de Producción Científica |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869414120982315008 |
| score |
15.811543 |